Hospital
Virtua Our Lady of Lourdes Hospital INC
Virtua Our Lady of Lourdes Hospital INC was paid $98.25M by Medicaid between Jan 2018 and Dec 2024, across 364 billing codes. Its largest line is 99284, emergency room visit (serious) — 32% of everything it billed.
33Billing provider infoVIRTUA OUR LADY OF LOURDES HOSPITAL INC
CAMDEN, NJ 08103
CAMDEN, NJ 08103
33aNPI1235134024assigned 06/17/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$98.25M
24GClaims1,645,677
24DCodes billed364
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#19 of 93
Median peer was paid$30.60M
This provider vs. median3.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 240,424 | $12.41M | |
| 2019 | 222,488 | $11.58M | |
| 2020 | 163,929 | $9.65M | |
| 2021 | 201,878 | $15.83M | |
| 2022 | 285,759 | $18.24M | |
| 2023 | 300,579 | $16.77M | |
| 2024incomplete | 230,620 | $13.78M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 32% | 75,977 | 68,477 | $31.06M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 54,437 | 51,323 | $16.86M |
| G0378 | Hospital observation service, per hour | 6.4% | 9,374 | 7,230 | $6.32M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 5.0% | 11,159 | 10,751 | $4.93M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.5% | 11,444 | 10,187 | $4.42M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.0% | 18,746 | 17,916 | $2.97M |
| OP272 | 2.2% | 12,231 | 9,835 | $2.13M | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.5% | 48,698 | 14,198 | $1.49M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.5% | 11,743 | 11,274 | $1.43M |
| 93017 | 1.4% | 5,755 | 5,459 | $1.34M | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.2% | 3,711 | 3,494 | $1.21M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.2% | 75,292 | 17,755 | $1.14M |
352 more codes
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 6,150 | $947K |
| OP278 | <1% | 924 | $854K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 5,852 | $754K |
| 93458 | <1% | 709 | $722K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 9,270 | $641K |
| 76830 | Ultrasound, transvaginal | <1% | 4,648 | $635K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 4,838 | $609K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 21,511 | $575K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 35,428 | $570K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 19,020 | $570K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,991 | $538K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 35,533 | $535K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 488 | $535K |
| OP370 | <1% | 6,784 | $513K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,181 | $509K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,898 | $457K |
| OP259 | <1% | 84,764 | $368K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 2,853 | $362K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 520 | $356K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 16,863 | $353K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 70,497 | $346K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 9,649 | $313K |
| 71045 | Radiologic examination, chest; single view | <1% | 15,118 | $296K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 69,965 | $284K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 13,586 | $276K |
| 74183 | <1% | 363 | $271K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 9,345 | $255K |
| 97161 | <1% | 6,936 | $244K | |
| 59025 | Fetal non-stress test | <1% | 2,178 | $239K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,567 | $211K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,446 | $211K |
| 93971 | <1% | 2,414 | $205K | |
| J3490 | Unclassified drugs | <1% | 34,885 | $193K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 499 | $177K |
| 49083 | <1% | 161 | $171K | |
| 71250 | <1% | 1,167 | $170K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,881 | $163K |
| C1769 | Guide wire | <1% | 1,650 | $158K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 10,570 | $145K |
| 72110 | <1% | 1,963 | $145K | |
| 0240U | <1% | 5,787 | $143K | |
| OP710 | <1% | 4,273 | $137K | |
| OP258 | <1% | 29,508 | $136K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 10,974 | $136K |
| 76536 | <1% | 1,066 | $134K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,428 | $131K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,495 | $130K |
| 73564 | <1% | 3,157 | $130K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,177 | $125K |
| 76642 | <1% | 1,324 | $125K | |
| 76801 | <1% | 2,778 | $125K | |
| 91200 | <1% | 1,817 | $124K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 9,013 | $124K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 3,235 | $122K |
| 93970 | <1% | 989 | $116K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 8,982 | $111K |
| 73630 | <1% | 3,258 | $110K | |
| A9270 | Non-covered item or service | <1% | 4,438 | $109K |
| 80076 | <1% | 36,118 | $108K | |
| 84484 | <1% | 25,219 | $108K | |
| 75574 | <1% | 210 | $107K | |
| 83880 | <1% | 8,363 | $99K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 227 | $98K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,268 | $95K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,551 | $91K |
| 76775 | <1% | 1,047 | $90K | |
| 73030 | <1% | 2,749 | $86K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,344 | $85K |
| 97164 | <1% | 2,141 | $84K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 60,962 | $83K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 9,123 | $82K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,350 | $77K |
| 97162 | <1% | 2,134 | $76K | |
| 80053 | Comprehensive metabolic panel | <1% | 9,757 | $74K |
| 77066 | Tomosynthesis, mammo | <1% | 472 | $74K |
| 73610 | <1% | 2,833 | $73K | |
| J2704 | Injection, propofol, 10 mg | <1% | 8,429 | $71K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 11,796 | $70K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 7,791 | $68K |
| 73130 | <1% | 2,381 | $67K | |
| 70486 | <1% | 643 | $67K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,849 | $60K |
| 93976 | <1% | 1,295 | $59K | |
| 80320 | <1% | 6,698 | $59K | |
| 85610 | <1% | 16,504 | $57K | |
| 81001 | <1% | 36,471 | $56K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 560 | $55K |
| OP250 | <1% | 7,549 | $54K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 72 | $49K |
| 85027 | <1% | 10,702 | $49K | |
| 76641 | <1% | 350 | $47K | |
| 83735 | <1% | 15,471 | $45K | |
| 70496 | <1% | 321 | $44K | |
| 73110 | <1% | 1,531 | $43K | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | <1% | 374 | $43K |
| 97113 | <1% | 780 | $41K | |
| 94644 | <1% | 2,861 | $41K | |
| 70498 | <1% | 313 | $39K | |
| 73502 | <1% | 1,346 | $38K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 865 | $38K |
| 85730 | <1% | 9,899 | $37K | |
| 83605 | <1% | 5,804 | $36K | |
| 84100 | <1% | 8,786 | $34K | |
| 72100 | <1% | 943 | $32K | |
| 82803 | <1% | 2,889 | $32K | |
| 86900 | <1% | 5,858 | $31K | |
| 86850 | <1% | 4,486 | $31K | |
| 80329 | <1% | 2,059 | $31K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,401 | $31K |
| 83690 | <1% | 16,012 | $30K | |
| 90715 | <1% | 1,986 | $30K | |
| 87040 | <1% | 4,293 | $29K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,754 | $28K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,273 | $28K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 20,618 | $28K |
| 87070 | <1% | 5,896 | $28K | |
| 80306 | <1% | 4,902 | $27K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 78 | $27K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,875 | $27K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 3,631 | $26K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,653 | $26K |
| 77065 | Tomosynthesis, mammo | <1% | 205 | $25K |
| 78431 | <1% | 17 | $25K | |
| 84702 | <1% | 4,203 | $24K | |
| 74022 | <1% | 982 | $24K | |
| 80061 | Lipid panel | <1% | 3,089 | $23K |
| 94664 | <1% | 3,594 | $23K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,748 | $23K |
| 84132 | <1% | 1,272 | $22K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,293 | $21K |
| 85379 | <1% | 6,883 | $21K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 610 | $20K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 112 | $20K |
| 93351 | <1% | 58 | $20K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,009 | $20K |
| 73562 | <1% | 378 | $19K | |
| 82962 | <1% | 15,315 | $19K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 595 | $19K |
| 74018 | <1% | 488 | $19K | |
| 82248 | <1% | 2,633 | $18K | |
| 97116 | <1% | 1,989 | $18K | |
| 87631 | <1% | 719 | $18K | |
| 88342 | <1% | 763 | $18K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 241 | $18K |
| 93798 | <1% | 474 | $18K | |
| 72050 | <1% | 293 | $17K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 855 | $17K |
| 87430 | <1% | 5,018 | $17K | |
| 77080 | <1% | 322 | $16K | |
| 87186 | <1% | 3,952 | $16K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 671 | $16K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,196 | $16K |
| 88304 | <1% | 856 | $16K | |
| 87088 | <1% | 6,785 | $16K | |
| 86901 | <1% | 5,938 | $16K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,485 | $15K |
| 87077 | <1% | 4,315 | $15K | |
| 81025 | <1% | 10,825 | $15K | |
| 36907 | <1% | 104 | $14K | |
| 76870 | <1% | 158 | $13K | |
| 82247 | <1% | 2,933 | $13K | |
| 97165 | <1% | 787 | $12K | |
| 80197 | <1% | 2,880 | $12K | |
| 81003 | <1% | 9,795 | $12K | |
| 93356 | <1% | 249 | $12K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 531 | $11K |
| 73080 | <1% | 440 | $11K | |
| 76942 | <1% | 431 | $11K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 113 | $11K |
| 72141 | <1% | 29 | $11K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 774 | $11K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 63 | $11K |
| 74174 | <1% | 66 | $10K | |
| J1815 | Injection, insulin, per 5 units | <1% | 2,882 | $10K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,281 | $10K |
| 96376 | <1% | 705 | $10K | |
| 82150 | <1% | 3,315 | $10K | |
| 36430 | <1% | 125 | $10K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,710 | $9K |
| 85014 | <1% | 458 | $9K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 500 | $9K |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 58 | $9K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,498 | $9K |
| 99152 | <1% | 1,008 | $9K | |
| OP229 | <1% | 170 | $9K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 889 | $8K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,803 | $8K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,515 | $8K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,145 | $7K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 522 | $7K |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 522 | $7K |
| 86403 | <1% | 1,513 | $7K | |
| 93307 | <1% | 36 | $7K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,729 | $7K |
| 87340 | <1% | 855 | $7K | |
| 87205 | <1% | 1,866 | $7K | |
| 73590 | <1% | 276 | $7K | |
| 73140 | <1% | 426 | $7K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,976 | $6K |
| 93623 | <1% | 16 | $6K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 670 | $6K |
| 86703 | <1% | 636 | $6K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 369 | $6K |
| 94760 | <1% | 3,980 | $6K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,458 | $5K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 6,881 | $5K |
| 72040 | <1% | 152 | $5K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 138 | $5K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 464 | $4K |
| 86803 | <1% | 326 | $4K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 43 | $4K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 285 | $4K |
| 87799 | <1% | 1,429 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,402 | $4K |
| 87420 | <1% | 1,029 | $4K | |
| 84703 | <1% | 1,211 | $4K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 165 | $4K |
| 85007 | <1% | 2,692 | $4K | |
| 96367 | <1% | 116 | $4K | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 3,564 | $4K |
| 76937 | <1% | 148 | $4K | |
| 86780 | <1% | 664 | $3K | |
| 72070 | <1% | 87 | $3K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 5,390 | $3K |
| 87581 | <1% | 226 | $3K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 393 | $3K |
| 97750 | <1% | 405 | $3K | |
| 82010 | <1% | 949 | $3K | |
| 81329 | <1% | 28 | $3K | |
| 81401 | <1% | 41 | $3K | |
| 82140 | <1% | 749 | $3K | |
| 87486 | <1% | 220 | $3K | |
| 84156 | <1% | 2,244 | $3K | |
| 82728 | <1% | 564 | $3K | |
| 87481 | <1% | 72 | $3K | |
| 73120 | <1% | 56 | $3K | |
| 97163 | <1% | 60 | $3K | |
| 82550 | <1% | 1,139 | $2K | |
| 94645 | <1% | 179 | $2K | |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | <1% | 253 | $2K |
| 84480 | <1% | 426 | $2K | |
| 82947 | <1% | 751 | $2K | |
| 88341 | <1% | 13 | $2K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 762 | $2K |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,381 | $2K |
| 99153 | Mod sedat endo service >5yrs | <1% | 495 | $2K |
| 87147 | <1% | 315 | $2K | |
| 82330 | <1% | 124 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 204 | $2K |
| 82607 | <1% | 350 | $2K | |
| 84295 | <1% | 107 | $2K | |
| 86140 | <1% | 1,236 | $2K | |
| 84439 | <1% | 453 | $2K | |
| 73700 | <1% | 13 | $2K | |
| 82375 | <1% | 728 | $2K | |
| 84436 | <1% | 514 | $2K | |
| 88142 | <1% | 98 | $2K | |
| 83021 | <1% | 86 | $2K | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | <1% | 116 | $2K |
| 77062 | <1% | 117 | $2K | |
| 74247 | <1% | 14 | $2K | |
| 73090 | <1% | 67 | $2K | |
| 86787 | <1% | 129 | $2K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 124 | $1K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 524 | $1K |
| 87512 | <1% | 72 | $1K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 74 | $1K |
| 95851 | <1% | 242 | $1K | |
| 70491 | <1% | 14 | $1K | |
| 29125 | <1% | 14 | $1K | |
| 71101 | <1% | 47 | $1K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 538 | $1K |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 2,478 | $1K |
| 86592 | <1% | 532 | $1K | |
| 72131 | <1% | 27 | $1K | |
| 85378 | <1% | 270 | $1K | |
| 85651 | <1% | 193 | $978.06 | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 32 | $867.56 |
| 89051 | <1% | 553 | $846.48 | |
| 90686 | <1% | 38 | $831.55 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 176 | $736.56 |
| 80361 | <1% | 135 | $729.52 | |
| 80365 | <1% | 122 | $639.11 | |
| 80367 | <1% | 134 | $637.89 | |
| 85652 | <1% | 1,065 | $613.99 | |
| 84145 | <1% | 95 | $605.68 | |
| 99001 | <1% | 474 | $603.20 | |
| 83050 | <1% | 622 | $595.00 | |
| 88313 | <1% | 24 | $594.73 | |
| 86706 | <1% | 206 | $575.54 | |
| 80356 | <1% | 134 | $524.45 | |
| 73560 | <1% | 14 | $521.27 | |
| 87522 | Neg quan hep c or qual rna | <1% | 38 | $521.24 |
| 80348 | <1% | 123 | $515.34 | |
| 80358 | <1% | 122 | $475.01 | |
| 80354 | <1% | 122 | $475.01 | |
| 85347 | <1% | 153 | $460.37 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 963 | $431.75 |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 21 | $419.80 |
| 83550 | <1% | 162 | $416.15 | |
| 87075 | <1% | 39 | $411.87 | |
| 73620 | <1% | 13 | $357.47 | |
| 78580 | <1% | 16 | $342.17 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 389 | $338.90 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 221 | $334.60 |
| 86923 | <1% | 63 | $329.51 | |
| A9540 | Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries | <1% | 28 | $304.98 |
| 78582 | <1% | 12 | $301.21 | |
| 86920 | <1% | 13 | $295.47 | |
| OP637 | <1% | 347 | $281.19 | |
| 94799 | <1% | 40 | $280.17 | |
| 83615 | <1% | 167 | $255.12 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 174 | $232.39 |
| A9558 | Xenon xe-133 gas, diagnostic, per 10 millicuries | <1% | 12 | $229.29 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 349 | $225.13 |
| 84466 | <1% | 27 | $217.19 | |
| 82570 | <1% | 178 | $189.39 | |
| 82043 | <1% | 97 | $169.79 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 1,207 | $167.24 |
| 82746 | <1% | 50 | $156.93 | |
| 95852 | <1% | 12 | $131.42 | |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | <1% | 17 | $123.94 |
| 80074 | <1% | 26 | $121.00 | |
| 87081 | <1% | 33 | $120.25 | |
| 84550 | <1% | 60 | $113.08 | |
| 86762 | <1% | 127 | $100.45 | |
| J2720 | Injection, protamine sulfate, per 10 mg | <1% | 16 | $100.19 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 12 | $93.98 |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 32 | $87.15 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 29 | $83.26 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 93 | $79.86 |
| 84075 | <1% | 235 | $76.81 | |
| 80321 | <1% | 73 | $68.31 | |
| 87015 | <1% | 45 | $63.99 | |
| 82977 | <1% | 64 | $48.72 | |
| 84450 | <1% | 236 | $48.35 | |
| 82950 | <1% | 17 | $48.00 | |
| 84460 | <1% | 236 | $40.54 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 62 | $31.10 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 206 | $29.56 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 172 | $29.56 |
| J7643 | Glycopyrrolate, inhalation solution, compounded product, administered through dme, unit dose form, per milligram | <1% | 73 | $29.07 |
| 78434 | <1% | 17 | $29.01 | |
| 83540 | <1% | 12 | $27.00 | |
| 84155 | <1% | 231 | $24.51 | |
| 82040 | <1% | 231 | $24.40 | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 116 | $23.00 |
| 88112 | <1% | 16 | $19.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 26 | $15.95 |
| 85018 | <1% | 37 | $14.14 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 19 | $13.43 |
| J1250 | Injection, dobutamine hydrochloride, per 250 mg | <1% | 21 | $8.83 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFERRARO, LISA (PRESIDENT)
Parent organizationOUR LADY OF LOURDES HEALTH CARE SERVICES, INC.
| Provider | Location | Paid |
|---|---|---|
| Ferraro Medical Associates, PA | Paterson, NJ | $98K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.